دورية أكاديمية
أعرض في EDS

Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers.

التفاصيل البيبلوغرافية
العنوان: Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers.
المؤلفون: Bradley SD; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Talukder AH; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Lai I; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Davis R; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Alvarez H; Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA., Tiriac H; Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, NY, USA., Zhang M; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Chiu Y; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Melendez B; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Jackson KR; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Katailiha A; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Sonnemann HM; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Li F; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Kang Y; Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Qiao N; Department of Breast Surgery Research, UT MD Anderson Cancer Center, Houston, TX, USA., Pan BF; Department of Systems Biology, UT MD Anderson Cancer Center, Houston, TX, USA., Lorenzi PL; Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, TX, USA., Hurd M; Ahmed Center for Pancreatic Cancer Research, UT MD Anderson Cancer Center, Houston, TX, USA., Mittendorf EA; Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Peterson CB; Department of Biostatistics, UT MD Anderson Cancer Center, Houston, TX, USA., Javle M; Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Bristow C; Center for Co-clinical Trials, UT MD Anderson Cancer Center, Houston, TX, USA., Kim M; Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Tuveson DA; Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, NY, USA., Hawke D; Department of Systems Biology, UT MD Anderson Cancer Center, Houston, TX, USA., Kopetz S; Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Wolff RA; Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Hwu P; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Maitra A; Department of Pathology, UT MD Anderson Cancer Center, Houston, TX, USA., Roszik J; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Yee C; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. cyee@mdanderson.org.; Department of Immunology, UT MD Anderson Cancer Center, Houston, TX, USA. cyee@mdanderson.org., Lizée G; Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. glizee@mdanderson.org.; Department of Immunology, UT MD Anderson Cancer Center, Houston, TX, USA. glizee@mdanderson.org.
المصدر: Nature communications [Nat Commun] 2020 Oct 21; Vol. 11 (1), pp. 5332. Date of Electronic Publication: 2020 Oct 21.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Antigens, Neoplasm/*immunology , Breast Neoplasms/*immunology , DNA-Binding Proteins/*immunology , Pancreatic Neoplasms/*immunology , Transcription Factors/*immunology, Antigens, Neoplasm/genetics ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/immunology ; Breast Neoplasms/genetics ; Carcinoma, Pancreatic Ductal/genetics ; Carcinoma, Pancreatic Ductal/immunology ; Carcinoma, Pancreatic Ductal/therapy ; Cell Line, Tumor ; Cytotoxicity, Immunologic ; DNA-Binding Proteins/genetics ; Female ; Gene Expression Profiling ; HLA-A1 Antigen/immunology ; Humans ; Immunotherapy, Adoptive ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/therapy ; Placenta/immunology ; Pregnancy ; Prognosis ; T-Lymphocytes, Cytotoxic/immunology ; Transcription Factors/genetics ; Pancreatic Neoplasms
مستخلص: Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for inducing clinical regressions by targeting tumor-associated antigens (TAA). To expand the TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we performed tandem mass spectrometry analysis of HLA class I-bound peptides from 35 PDAC patient tumors. This identified a shared HLA-A*0101 restricted peptide derived from co-transcriptional activator Vestigial-like 1 (VGLL1) as a putative TAA demonstrating overexpression in multiple tumor types and low or absent expression in essential normal tissues. Here we show that VGLL1-specific CTLs expanded from the blood of a PDAC patient could recognize and kill in an antigen-specific manner a majority of HLA-A*0101 allogeneic tumor cell lines derived not only from PDAC, but also bladder, ovarian, gastric, lung, and basal-like breast cancers. Gene expression profiling reveals VGLL1 as a member of a unique group of cancer-placenta antigens (CPA) that may constitute immunotherapeutic targets for patients with multiple cancer types.
References: Front Immunol. 2018 May 14;9:1044. (PMID: 29868007)
Mol Ther. 2011 Mar;19(3):620-6. (PMID: 21157437)
Cancer Discov. 2018 Sep;8(9):1069-1086. (PMID: 30115704)
N Engl J Med. 2016 Dec 8;375(23):2255-2262. (PMID: 27959684)
Oncotarget. 2018 Feb 13;9(19):14764-14790. (PMID: 29599906)
Endocr Relat Cancer. 2014 Aug;21(4):587-99. (PMID: 24891455)
Sci Transl Med. 2013 Feb 27;5(174):174ra27. (PMID: 23447018)
J Immunol. 2017 Nov 1;199(9):3360-3368. (PMID: 28978689)
Oncol Lett. 2018 Apr;15(4):5924-5932. (PMID: 29556312)
Blood. 2013 Aug 8;122(6):863-71. (PMID: 23770775)
Cancer Immunol Res. 2020 Jun;8(6):794-805. (PMID: 32213626)
Blood. 2017 Nov 2;130(18):1985-1994. (PMID: 28860210)
Development. 2018 Jan 29;145(2):. (PMID: 29361559)
Int J Mol Sci. 2016 Jan 21;17(1):. (PMID: 26805820)
J Clin Oncol. 2005 Apr 1;23(10):2346-57. (PMID: 15800326)
Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900)
Beijing Da Xue Xue Bao Yi Xue Ban. 2006 Apr 18;38(2):124-7. (PMID: 16617350)
Science. 2015 Apr 3;348(6230):124-8. (PMID: 25765070)
Science. 2015 Oct 9;350(6257):207-211. (PMID: 26359337)
Tumour Biol. 2017 Apr;39(4):1010428317695928. (PMID: 28381175)
Cancer. 2016 Dec 15;122(24):3765-3775. (PMID: 27649047)
Sci Transl Med. 2013 Aug 7;5(197):197ra103. (PMID: 23926201)
Am J Surg Pathol. 2011 May;35(5):e34-46. (PMID: 21490442)
Trends Cancer. 2018 Jun;4(6):418-428. (PMID: 29860986)
Cancer Immunol Res. 2015 Jun;3(6):602-9. (PMID: 25795007)
Science. 2015 Dec 11;350(6266):1387-90. (PMID: 26516200)
Am J Obstet Gynecol. 2009 Jan;200(1):75.e1-10. (PMID: 18976739)
Mol Cancer. 2017 Apr 11;16(1):77. (PMID: 28399871)
Clin Cancer Res. 2015 Mar 1;21(5):1019-27. (PMID: 25538264)
Cancer Immun. 2007 Nov 06;7:18. (PMID: 17983203)
J Immunol. 2005 Aug 15;175(4):2261-9. (PMID: 16081794)
Immunol Rev. 2014 Jan;257(1):56-71. (PMID: 24329789)
Structure. 2012 Jul 3;20(7):1135-40. (PMID: 22632831)
Gastroenterology. 2018 Jul;155(1):29-32. (PMID: 29567081)
Development. 1999 Nov;126(21):4807-16. (PMID: 10518497)
Nature. 2017 Nov 23;551(7681):512-516. (PMID: 29132146)
Front Immunol. 2018 Sep 25;9:2166. (PMID: 30319627)
Int J Cancer. 2008 May 1;122(9):2038-43. (PMID: 18183594)
Front Immunol. 2018 Aug 15;9:1878. (PMID: 30158932)
Blood. 2008 Jan 1;111(1):229-35. (PMID: 17921346)
J Exp Med. 2016 Jun 27;213(7):1133-9. (PMID: 27242164)
Nature. 2016 Mar 3;531(7592):47-52. (PMID: 26909576)
Clin Cancer Res. 2012 Dec 15;18(24):6758-70. (PMID: 23032743)
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. (PMID: 29093164)
Ther Adv Med Oncol. 2018 Dec 17;10:1758835918816281. (PMID: 30574212)
Nat Med. 2018 Jun;24(6):724-730. (PMID: 29867227)
Expert Opin Ther Targets. 2018 Aug;22(8):675-686. (PMID: 29999426)
Nucleic Acids Res. 2015 Jan;43(Database issue):D784-8. (PMID: 25414323)
Dev Genes Evol. 2016 Jul;226(4):297-315. (PMID: 27116603)
Mol Cancer. 2018 Sep 3;17(1):134. (PMID: 30176928)
N Engl J Med. 2017 Dec 21;377(25):2500-2501. (PMID: 29262275)
Cancer Cell. 2015 Nov 9;28(5):638-652. (PMID: 26525103)
Annu Rev Med. 2013;64:71-90. (PMID: 23092383)
Nat Rev Mol Cell Biol. 2019 Apr;20(4):211-226. (PMID: 30546055)
Pancreas. 2015 Jul;44(5):693-712. (PMID: 25931254)
J Cancer. 2016 Jul 07;7(11):1497-514. (PMID: 27471566)
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861. (PMID: 30487695)
Chembiochem. 2014 Mar 3;15(4):537-42. (PMID: 24504694)
J Immunother. 2013 Feb;36(2):133-51. (PMID: 23377668)
Science. 2006 Oct 6;314(5796):126-9. (PMID: 16946036)
J Clin Oncol. 2016 Nov 1;34(31):3787-3795. (PMID: 27269940)
Genome Med. 2016 Mar 30;8(1):33. (PMID: 27029192)
Nat Rev Clin Oncol. 2019 Jan;16(1):11-26. (PMID: 30341417)
Cancer Immunol Res. 2016 Mar;4(3):204-14. (PMID: 26701267)
Ann Gastroenterol Surg. 2018 Jun 22;2(4):274-281. (PMID: 30003190)
J Transl Med. 2015 Mar 28;13:102. (PMID: 25890361)
Cancer Immunol Res. 2017 Aug;5(8):618-629. (PMID: 28630054)
معلومات مُعتمدة: P30 CA016672 United States CA NCI NIH HHS; P50 CA221707 United States CA NCI NIH HHS; R01 CA218004 United States CA NCI NIH HHS; R01 CA237672 United States CA NCI NIH HHS; R01 CA220236 United States CA NCI NIH HHS; P30 CA045508 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Antigens, Neoplasm)
0 (Biomarkers, Tumor)
0 (DNA-Binding Proteins)
0 (HLA-A*01:01 antigen)
0 (HLA-A1 Antigen)
0 (Transcription Factors)
0 (VGLL1 protein, human)
تواريخ الأحداث: Date Created: 20201022 Date Completed: 20201109 Latest Revision: 20231213
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7577998
DOI: 10.1038/s41467-020-19141-w
PMID: 33087697
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-020-19141-w